Physician profile
James C Runyon
NPI 1710721402
$2,116.11
in general payments reported to CMS, 2019-2025
11 companies · $846 in 2025
The $846 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,270 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.12 |
| Education | $146.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.15 | 2024-2025 | |
| Janssen Biotech, INC. | $442.08 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $228.03 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $217.92 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $208.69 | 2024-2025 | Zoryve |
| Incyte Corporation | $172.88 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $114.25 | 2024-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $75.19 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $60.69 | 2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $44.12 | 2024-2025 | |
| Pfizer INC. | $24.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Runyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.